M Ventures
M Ventures invests in innovative technologies and products with the potential to significantly impact Merck‘s core business areas.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed M Ventures Information
Geographic Data
Address: Gustav Mahlerplein 102 Toyo lto Building
City: Amsterdam
State: noord-holland
Zip: 1082 MA
Country: NL
Financial Info
Stage:
Raised Last:
$0
Raised Total:$677M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
8,401,931Website Global Rank
315Website Monthly Traffic
Twitter Followers
Description
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2014 | Bird Rock Bio | Series B | 0 |
| 4/2019 | Sonde Health | Series A | 0 |
| 9/2021 | Legendairy Foods | Series A | 0 |
| 1/2020 | iOnctura | Series A | 16.6M |
| 2/2021 | Metalenz | Series A | 10M |
| 6/2023 | Celestial AI | Series B | 100M |
| 2/2014 | Synaffix BV | Series A | - |
| 1/2012 | Galecto | Seed Round | - |
| 4/2013 | Canbex Therapeutics | Venture Round | 3.2M |
| 11/2017 | Wiliot | Series A | 5M |
| 11/2021 | Biolinq | Series B | 0 |
| 3/2017 | Medisafe | Series B | 0 |
| 8/2018 | ApoGen Biotechnologies | Series A | 4M |
| 1/2017 | ARTSaVIT | Series A | 6.3M |
| 9/2020 | NanoSyrinx | Pre Seed Round | - |
| 1/2017 | Macrophage Pharma | Series A | 0 |
| 7/2021 | Wiliot | Series C | 0 |
| 11/2020 | F-Star Therapeutics | Post-IPO Equity | 0 |
| 7/2020 | iOnctura | Series A | 5.8M |
| 5/2018 | Gamelynx | Equity | 1.2M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 2/2017 | Prexton Therapeutics | Series B | 31.1M |
| 10/2018 | Galecto | Series C | 90.2M |
| 8/2018 | Vantage Point | Pre Seed Round | 1.4M |
| 11/2021 | NeoLogic (VLSI) | Seed Round | 2.8M |
| 7/2021 | Artios Pharma | Series C | 0 |
| 3/2022 | Concerto Biosciences | Equity | 24.5M |
| 5/2019 | Storm Therapeutics | Series A | 17.8M |
| 7/2019 | Forendo Pharma | Venture Round | 0 |
| 9/2016 | Artios Pharma | Series A | 0 |
| 6/2017 | Indi Molecular | Series A | 0 |
| 5/2020 | SynSense | Series A | - |
| 7/2021 | NanoSyrinx | Seed Round | 8.5M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 7/2020 | DNA Script | Series B | 50M |
| 2/2018 | FanAI | Venture Round | 0 |
| 11/2018 | curbFlow | Seed Round | - |
| 11/2020 | Ferroelectric Memory Company | Series B | 0 |
| 2/2015 | Prexton Therapeutics | Series A | 10M |
| 10/2013 | Galecto | Series B | 6.3M |
| 8/2018 | Vantage Point | Pre Seed Round | 0 |
| 7/2016 | Akili Interactive Labs | Series B | 42.4M |
| 1/2012 | Translate Bio | Series A | 20.7M |
| 10/2021 | DNA Script | Series C | 0 |
| 12/2022 | Storm Therapeutics | Series B | 30M |
| 10/2022 | Nucleome Therapeutics | Series A | 42.3M |
| 10/2017 | aveni | Series B | 10.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 7/2015 | Translate Bio | Series B | 0 |
| 6/2018 | Mighty Bear Games | Seed Round | 2.5M |
| 1/2021 | Theolytics | Series A | 6.8M |
| 10/2014 | Forendo Pharma | Series A | 0 |
| 6/2018 | Inthera Bioscience | Series A | 0 |
| 2/2022 | Celestial AI | Series A | 56M |
| 7/2018 | Mosa Meat | Series A | 0 |
| 3/2022 | Concerto Biosciences | Series A | 24.5M |
| 12/2019 | Neurable | Series A | 6M |
| 4/2011 | F-Star Therapeutics | Venture Round | 0 |
| 2/2022 | Micropsi Industries | Series B | 0 |
| 9/2020 | Tipe | Seed Round | 2.1M |
| 3/2023 | PxE | Seed Round | 0 |
| 3/2019 | Biolinq | Series A | 4.8M |
| 11/2017 | Biolinq | Series A | 0 |
| 10/2013 | F-Star Therapeutics | Series A | 0 |
| 6/2020 | Micropsi Industries | Series A | - |
| 5/2009 | Bird Rock Bio | Series A | 13M |
| 1/2010 | F-Star Therapeutics | Series A | 11.5M |
| 4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
| 1/2018 | Rewind Therapeutics | Series A | 18.3M |
| 10/2014 | Raze Therapeutics | Series A | 24M |
| 1/2023 | Rewind Therapeutics | Series A | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 4/2016 | Metabomed | Series A | 18M |
| 2/2020 | Scipio Bioscience | Series A | 6.5M |
| 6/2016 | Storm Therapeutics | Series A | 16M |
| 7/2019 | SIMULATE | Seed Round | 7M |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 9/2020 | SeeQC | Series A | 22.4M |
| 3/2022 | Altoida | Series A | 0 |
| 9/2018 | Forendo Pharma | Venture Round | 0 |
| 5/2017 | Inthera Bioscience | Series A | 0 |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 1/2023 | Rewind Therapeutics | Series B | - |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 7/2016 | Progyny | Series B | 14.7M |
| 2/2021 | Medisafe | Series C | 0 |
| 6/2023 | Astraveus | Seed Round | 0 |
| 5/2018 | Akili Interactive Labs | Series C | 0 |
| 5/2021 | Akili Interactive Labs | Series D | 0 |
| 2/2022 | Plexium | Series B | 0 |
| 10/2022 | Metalenz | Series B | 0 |
| 11/2019 | ResoTher Pharma | Seed Round | 2.4M |
| 5/2019 | Altoida | Series A | 6.3M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 4/2021 | Anavo Therapeutics | Seed Round | 0 |
| 2/2018 | FanAI | Seed Round | 2.5M |
| 5/2021 | MemryX | Series A | - |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 12/2022 | Sonde Health | Series B | 19.3M |
| 5/2022 | PictorLabs | Series A | 0 |
| 9/2020 | Mosa Meat | Series B | 0 |
| 8/2017 | Alcan Systems | Series A | 8.8M |
| 2/2023 | UNISERS | Seed Round | 14M |
| 6/2017 | iOnctura | Seed Round | - |
| 4/2014 | Padlock Therapeutics | Series A | 14.7M |
| 3/2013 | Calypso Biotech | Seed Round | 3.3M |
| 9/2021 | Calypso Biotech | Series A | 0 |
| 4/2009 | Ambrx | Series D | 10M |
| 2/2019 | Calypso Biotech | Series A | 22.7M |
| 10/2017 | Peratech | Equity | 12.4M |
| 6/2009 | Anaphore | Series A | 13M |
| 1/2022 | Future Fertility | Series A | - |
| 3/2022 | Altoida | Series A | 0 |
| 2/2022 | Plexium | Series B | 0 |
| 2/2022 | Micropsi Industries | Series B | 0 |
| 2/2022 | Celestial AI | Series A | 0 |
| 1/2022 | Future Fertility | Series A | - |
| 11/2021 | NeoLogic (VLSI) | Seed Round | 0 |
| 11/2021 | Biolinq | Series B | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 9/2021 | Legendairy Foods | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
